drugset / Trial / NCT01417000

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

NCT01417000

RandomizedParallel-groupOpen-labelTreatment

Summary

Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.

Timeline

Start
2011-09-21
Primary completion
2016-10
Completion
2017-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CRS-207 Vaccine 1e+09 unknown Intravenous
Subject GVAX Pancreas Vaccine 5e+08 cells Other
Background Cyclophosphamide Other / unclassified 200 mg/m2 Intravenous